Data from first DMT-assisted clinical trial revealed
No sign of significant negative effects on anxiety and wellbeing following pioneering Small Pharma trial
Read More
Tag: MDD
Janssen disappointed with second NICE no for Spravato
NICE has concerns with the evidence submitted but Janssen insists the nasal spray is a cost-effective use of NHS resources
Read More
Acadia pulls plug on pimavanserin for adjunctive MDD
US regulators have, however, accepted the drug for review to treat hallucinations and delusions associated with dementia-related psychosis
Read More
Allergan’s rapastinel fails to hit key targets in depression trials
Allergan’s rapastinel has failed to hit its primary endpoints in three late-stage studies assessing its potential as an adjunctive treatment for depression.
Read More
FDA advisors turn down Alkermes’ ALKS 5461
Alkermes’ ALKS 5461 has been hit with a potential setback in the US after regulatory advisors failed to back its approval for major depressive disorder (MDD).
Read More
Janssen files nasal spray for depression
Janssen has submitted a marketing application to the European Medicines Agency (EMA) seeking approval of investigational nasal spray esketamine for the treatment of major depressive disorder.
Read More
Allergan to move Botox into PhIII for depression
Allergan has reported mixed top-line data from a mid-stage trial testing Botox as a treatment for major depressive disorder (MDD), but says the results are “encouraging” and warrant a move into Phase III development.
Read More
Alkermes boosted by trial success for antidepressant
Shares in Ireland-headquartered Alkermes shot up nearly 50 percent after its experimental depression drug hit targets in a pivotal late-stage trial.
Read More
- MRM Health collaborates with Oncode Institute and Netherlands Cancer Institute
- Sobi to acquire Arthrosi Therapeutics, strengthening gout treatment pipeline
- Lindus Health and Quotient Sciences announce strategic partnership to accelerate drug development
- Title21 Health Solutions joins the Blood and Cells Advocacy Roster
- NADMED launches $30,000 metabolomics research award
